U.S. Hemophilia Treatment Market Anticipated to Witness High Growth Owing to Rising Prevalence of Inherited Bleeding Disorders

U.S. Hemophilia Treatment Market Anticipated to Witness High Growth Owing to Rising Prevalence of Inherited Bleeding Disorders

The U.S. hemophilia treatment market comprises various types of drugs such as plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates and desmopressin that are used to prevent and control bleeding episodes in patients with hemophilia. The recombinant coagulation factor concentrates segment holds a major share in the market due to advantages over plasma-derived coagulation factor concentrates. Hemophilia is a rare inherited bleeding disorder marked by prolonged or spontaneous bleeding from minor cuts, gums, bruising etc. due to lack of coagulation factors in the blood. According to some estimates, around 20,000 individuals suffer from hemophilia in the U.S. The rising prevalence of inherited bleeding disorders such as hemophilia A and hemophilia B and continuous pipeline of novel hemophilia drugs are major factors fueling the demand for hemophilia treatment drugs in the country.

The Global U.S. Hemophilia Treatment Market Size is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. hemophilia treatment are Takeda Pharmaceutical Company Limited, Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc. and others. Key players are investing heavily in the development of improved hemophilia treatment drugs through strategic alliances and acquisitions. For instance, in 2020, Takeda Pharmaceutical acquired worldwide development and manufacturing rights to an investigational hemophilia A treatment from Emergent BioSolutions. The rising prevalence of hemophilia presents significant market opportunity for key players. Novel therapies in pipeline including extended half-life factors, non-factors therapies and gene therapies hold potential to further expand the market size. For example, Spark Therapeutics’ investigational gene therapy Valoctocogene Roxaparvovec (SPK-9001) gained FDA priority review in 2021 and is expected to be approved soon.

Key players are focusing on global expansion through collaborations to strengthen their presence worldwide. For instance, in 2021, Sanofi partnered with Swedish Orphan Biovitrum to expand global reach for hemophilia products. Baxter has collaborative agreements with Biogen and other players for hemophilia products distribution in different regions.

Market Drivers

Rising prevalence of inherited bleeding disorders such as hemophilia A and B: According to CDC, around 1 in 5,000 male births in the U.S. have hemophilia. The increasing diagnosis rate is driving the hemophilia treatment market.

Advancements in hemophilia treatment: Continued innovations are improving the efficacy, safety and convenience of hemophilia drugs. Novel drugs in pipeline have potential to revolutionize treatment. For e.g extended half-life factor concentrate drugs require less frequent dosing.

Market Restraints

High Cost Of Hemophilia Drugs: Hemophilia drugs have high drug development and manufacturing costs which leads to their high prices. This makes long-term treatment unaffordable for many. For e.g annual cost of novel extended half-life factors is over USD300,000.Shortage Of Clotting Factor Concentrates: Supply shortage remains a concern affecting patient care. Key challenges include limited raw material availability and manufacturing capacity constraints.

Segment Analysis 

The U.S hemophilia treatment market is segmented into product and disease indication. The product segment includes plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, and desmopressin. Among these, recombinant coagulation factor concentrates dominates the segment, accounting for over 70% market share due to low risk of disease transmission and convenient usage. The disease indication segment is further divided into hemophilia A and hemophilia B. Hemophilia A accounts for around 80% of the cases and holds the largest market share. This is because hemophilia A has high prevalence rate compared to hemophilia B.

Regional Analysis

The North America region dominates the global hemophilia treatment market with the largest share. This is attributed to presence of well-established healthcare system, awareness levels regarding hemophilia and related treatment options are high. Additionally, availability of advanced treatment products and presence of key market players fuels the market growth. The region is estimated to grow at CAGR 5.8% during the forecast period.

What Are The Key Data Covered In This U.S. Hemophilia Treatment Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the U.S. Hemophilia Treatment Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the U.S. Hemophilia Treatment Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- U.S. Hemophilia Treatment Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of U.S. Hemophilia Treatment Market vendors

FAQ’S

Q.1 What are the main factors influencing the U.S. Hemophilia Treatment market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top U.S. Hemophilia Treatment Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the U.S. Hemophilia Treatment market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.marketwebjournal.com/u-s-hemophilia-treatment-market-trend-size-and-demand/